The [18F]FDG μPET Readout of a Brain Activation Model to Evaluate the Metabotropic Glutamate Receptor 2 Positive Allosteric Modulator JNJ-42153605
暂无分享,去创建一个
Steven Staelens | Xavier Langlois | Sigrid Stroobants | Tine Wyckhuys | X. Langlois | S. Stroobants | S. Staelens | L. Wyffels | T. Wyckhuys | Mark Schmidt | Leonie Wyffels | M. Schmidt
[1] R. Dean,et al. Effects of a novel mGlu2/3 receptor agonist prodrug, LY2140023 monohydrate, on central monoamine turnover as determined in human and rat cerebrospinal fluid , 2011, Psychopharmacology.
[2] F. Nicoletti,et al. Metabotropic glutamate receptors and the control of chronic pain. , 2012, Current opinion in pharmacology.
[3] H. Gunduz-Bruce,et al. The acute effects of NMDA antagonism: From the rodent to the human brain , 2009, Brain Research Reviews.
[4] D. Lorrain,et al. Group II mGlu Receptor Activation Suppresses Norepinephrine Release in the Ventral Hippocampus and Locomotor Responses to Acute Ketamine Challenge , 2003, Neuropsychopharmacology.
[5] C. Parsons,et al. Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo , 1995, Neuropharmacology.
[6] J. Gabrieli,et al. Hyperactivity and hyperconnectivity of the default network in schizophrenia and in first-degree relatives of persons with schizophrenia , 2009, Proceedings of the National Academy of Sciences.
[7] D. Sheffler,et al. The mGluR2 Positive Allosteric Modulator BINA Decreases Cocaine Self-Administration and Cue-Induced Cocaine-Seeking and Counteracts Cocaine-Induced Enhancement of Brain Reward Function in Rats , 2010, Neuropsychopharmacology.
[8] P. Seeman. An agonist at glutamate and dopamine D2 receptors, LY404039 , 2013, Neuropharmacology.
[9] María Lourdes Linares,et al. Discovery of 3-cyclopropylmethyl-7-(4-phenylpiperidin-1-yl)-8-trifluoromethyl[1,2,4]triazolo[4,3-a]pyridine (JNJ-42153605): a positive allosteric modulator of the metabotropic glutamate 2 receptor. , 2012, Journal of medicinal chemistry.
[10] R. Mailman,et al. Differential effects of clozapine and haloperidol on ketamine-induced brain metabolic activation , 1998, Brain Research.
[11] Merryl D. Cramer,et al. Biphenyl-indanones: allosteric potentiators of the metabotropic glutamate subtype 2 receptor. , 2005, Bioorganic & medicinal chemistry letters.
[12] P. Conn,et al. Biphenyl-indanone A, a Positive Allosteric Modulator of the Metabotropic Glutamate Receptor Subtype 2, Has Antipsychotic- and Anxiolytic-Like Effects in Mice , 2006, Journal of Pharmacology and Experimental Therapeutics.
[13] K. Perry,et al. In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders , 2007, Psychopharmacology.
[14] D. Schoepp,et al. Evidence for the Role of Metabotropic Glutamate (mGlu)2 Not mGlu3 Receptors in the Preclinical Antipsychotic Pharmacology of the mGlu2/3 Receptor Agonist (–)-(1R,4S,5S,6S)-4-Amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic Acid (LY404039) , 2008, Journal of Pharmacology and Experimental Therapeutics.
[15] D. Javitt,et al. Recent advances in the phencyclidine model of schizophrenia. , 1991, The American journal of psychiatry.
[16] H. Möller,et al. Hypermetabolic pattern in frontal cortex and other brain regions in unmedicated schizophrenia patients , 2005, European Archives of Psychiatry and Clinical Neuroscience.
[17] P. Conn,et al. A Selective Allosteric Potentiator of Metabotropic Glutamate (mGlu) 2 Receptors Has Effects Similar to an Orthosteric mGlu2/3 Receptor Agonist in Mouse Models Predictive of Antipsychotic Activity , 2005, Journal of Pharmacology and Experimental Therapeutics.
[18] Sophie Lancelot,et al. Small-animal positron emission tomography as a tool for neuropharmacology. , 2010, Trends in pharmacological sciences.
[19] B. Moghaddam,et al. Impact of metabotropic glutamate 2/3 receptor stimulation on activated dopamine release and locomotion , 2010, Psychopharmacology.
[20] Jeffrey A Lieberman,et al. Effects of Ketamine, MK-801, and Amphetamine on Regional Brain 2-Deoxyglucose Uptake in Freely Moving Mice , 2000, Neuropsychopharmacology.
[21] G. Marek,et al. In Vitro and in Vivo Evidence for a Lack of Interaction with Dopamine D2 Receptors by the Metabotropic Glutamate 2/3 Receptor Agonists 1S,2S,5R,6S-2-Aminobicyclo[3.1.0]hexane-2,6-bicaroxylate Monohydrate (LY354740) and (−)-2-Oxa-4-aminobicyclo[3.1.0] Hexane-4,6-dicarboxylic Acid (LY379268) , 2009, Journal of Pharmacology and Experimental Therapeutics.
[22] Christian Lüscher,et al. Group 1 mGluR-Dependent Synaptic Long-Term Depression: Mechanisms and Implications for Circuitry and Disease , 2010, Neuron.
[23] P Jeffrey Conn,et al. Glutamate receptors as therapeutic targets for Parkinson's disease. , 2009, CNS & neurological disorders drug targets.
[24] E. Walker,et al. Neuromotor precursors of schizophrenia. , 1994, Schizophrenia bulletin.
[25] J. Newcomer,et al. NMDA receptor hypofunction model of schizophrenia. , 1999, Journal of psychiatric research.
[26] C. Parsons,et al. Potency, voltage-dependency, agonist concentration-dependency, blocking kinetics and partial untrapping of the uncompetitive N-methyl-d-aspartate (NMDA) channel blocker memantine at human NMDA (GluN1/GluN2A) receptors , 2009, Neuropharmacology.
[27] X. Langlois,et al. Memantine-induced brain activation as a model for the rapid screening of potential novel antipsychotic compounds: exemplified by activity of an mGlu2/3 receptor agonist , 2011, Psychopharmacology.
[28] S. Mosolov,et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial , 2007, Nature Medicine.
[29] A. Periclou,et al. Pharmacokinetic study of memantine in healthy and renally impaired subjects , 2006, Clinical pharmacology and therapeutics.
[30] Karl J. Friston,et al. The Computational Anatomy of Psychosis , 2013, Front. Psychiatry.
[31] C. Bissantz,et al. Structural determinants of allosteric antagonism at metabotropic glutamate receptor 2: mechanistic studies with new potent negative allosteric modulators , 2011, British journal of pharmacology.
[32] J. Pierri,et al. Lamina-specific deficits in parvalbumin-immunoreactive varicosities in the prefrontal cortex of subjects with schizophrenia: evidence for fewer projections from the thalamus. , 2001, The American journal of psychiatry.
[33] D. Schoepp,et al. Regulation of Neurotransmitter Release by Metabotropic Glutamate Receptors , 2000, Journal of neurochemistry.
[34] S. Chaki,et al. Mood disorders: regulation by metabotropic glutamate receptors. , 2008, Biochemical pharmacology.
[35] Craig W Lindsley,et al. Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia. , 2009, Trends in pharmacological sciences.
[36] C. C. Watson,et al. New, faster, image-based scatter correction for 3D PET , 1999, 1999 IEEE Nuclear Science Symposium. Conference Record. 1999 Nuclear Science Symposium and Medical Imaging Conference (Cat. No.99CH37019).
[37] G. Marek,et al. N-(4-((2-(trifluoromethyl)-3-hydroxy-4-(isobutyryl)phenoxy)methyl)benzyl)-1-methyl-1H-imidazole-4-carboxamide (THIIC), a Novel Metabotropic Glutamate 2 Potentiator with Potential Anxiolytic/Antidepressant Properties: In Vivo Profiling Suggests a Link between Behavioral and Central Nervous System Neu , 2011, Journal of Pharmacology and Experimental Therapeutics.
[38] J. Clements,et al. Pharmacokinetics and analgesic effect of ketamine in man. , 1981, British journal of anaesthesia.
[39] W. Shipe,et al. Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia. , 2006, Current topics in medicinal chemistry.
[40] David W. Townsend,et al. Positron Emission Tomography , 1985, Other Conferences.
[41] J. Kemp,et al. Ionotropic and metabotropic glutamate receptor structure and pharmacology , 2005, Psychopharmacology.
[42] G. Breese,et al. Metabolic mapping of the rat brain after subanesthetic doses of ketamine: potential relevance to schizophrenia , 1998, Brain Research.
[43] J. Wierońska,et al. On the mechanism of anti-hyperthermic effects of LY379268 and LY487379, group II mGlu receptors activators, in the stress-induced hyperthermia in singly housed mice , 2012, Neuropharmacology.
[44] Anat Biegon,et al. Serial microPET measures of the metabolic reaction to a microdialysis probe implant , 2006, Journal of Neuroscience Methods.
[45] T. Eichele,et al. Increased Intrinsic Brain Activity in the Striatum Reflects Symptom Dimensions in Schizophrenia , 2012, Schizophrenia bulletin.
[46] C. Elmore,et al. Absence of direct effects on the dopamine D2 receptor by mGluR2/3‐selective receptor agonists LY 354,740 and LY 379,268 , 2011, Synapse.
[47] H. Schoemaker,et al. Effects of a Positive Allosteric Modulator of Group II Metabotropic Glutamate Receptors, LY487379, on Cognitive Flexibility and Impulsive-Like Responding in Rats , 2010, Journal of Pharmacology and Experimental Therapeutics.
[48] P. Andiné,et al. Characterization of MK-801-induced behavior as a putative rat model of psychosis. , 1999, The Journal of pharmacology and experimental therapeutics.
[49] G. Muehllehner,et al. Positron emission tomography , 2006, Physics in medicine and biology.
[50] D. Sheffler,et al. Design and synthesis of an orally active metabotropic glutamate receptor subtype-2 (mGluR2) positive allosteric modulator (PAM) that decreases cocaine self-administration in rats. , 2011, Journal of medicinal chemistry.
[51] P. Conn,et al. Metabotropic glutamate receptors as therapeutic targets for schizophrenia , 2012, Neuropharmacology.
[52] Rick A Adams,et al. Patterns of anterior cingulate activation in schizophrenia: a selective review , 2007, Neuropsychiatric disease and treatment.
[53] Y. Izumi,et al. Indistinguishable Synaptic Pharmacodynamics of the N-Methyl-d-Aspartate Receptor Channel Blockers Memantine and Ketamine , 2013, Molecular Pharmacology.
[54] P. Seeman,et al. Glutamate agonist LY404,039 for treating schizophrenia has affinity for the dopamine D2High receptor , 2009, Synapse.
[55] D. Schoepp,et al. Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: synthesis and subtype selectivity of N-(4-(2-methoxyphenoxy)phenyl)-N-(2,2,2- trifluoroethylsulfonyl)pyrid-3-ylmethylamine. , 2003, Journal of medicinal chemistry.